Business Context and Reporting Period
This Form 8-K is a current report filed by Aclaris Therapeutics, Inc. on February 8, 2019, regarding events occurring on February 7, 2019. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate governance event.
Material Changes
- Executive Departure: Effective February 7, 2019, Brett Fair is no longer employed by the Company.
- Role: Mr. Fair served as the Chief Commercial Officer.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies related to the company's operations or financial condition. The departure of the Chief Commercial Officer is reported as an "Other Event" under Item 8.01.
Investor Verification Checklist
- Verify the effective date of Brett Fair's departure (February 7, 2019).
- Confirm if a successor has been appointed for the Chief Commercial Officer role.
- Review subsequent filings for any impact on commercial strategy or pipeline development.